Renaissance Technologies’s IGM Biosciences IGMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-117,734
| Closed | -$132K | – | 3680 |
|
|
2025
Q2 | $132K | Buy |
117,734
+82,434
| +234% | +$101K | ﹤0.01% | 3254 |
|
|
2025
Q1 | $40.6K | Sell |
35,300
-40,500
| -53% | -$75.3K | ﹤0.01% | 3308 |
|
|
2024
Q4 | $463K | Buy |
75,800
+9,300
| +14% | +$110K | ﹤0.01% | 2873 |
|
|
2024
Q3 | $1.1M | Sell |
66,500
-42,193
| -39% | -$462K | ﹤0.01% | 2382 |
|
|
2024
Q2 | $747K | Buy |
108,693
+60,593
| +126% | +$518K | ﹤0.01% | 2486 |
|
|
2024
Q1 | $464K | Buy |
48,100
+11,500
| +31% | +$133K | ﹤0.01% | 2894 |
|
|
2023
Q4 | $304K | Sell |
36,600
-54,300
| -60% | -$315K | ﹤0.01% | 2981 |
|
|
2023
Q3 | $759K | Sell |
90,900
-85,100
| -48% | -$722K | ﹤0.01% | 2481 |
|
|
2023
Q2 | $1.62M | Buy |
176,000
+133,300
| +312% | +$1.49M | ﹤0.01% | 2134 |
|
|
2023
Q1 | $587K | Sell |
42,700
-50,100
| -54% | -$1.04M | ﹤0.01% | 2795 |
|
|
2022
Q4 | $1.58M | Buy |
92,800
+80,200
| +637% | +$1.6M | ﹤0.01% | 2226 |
|
|
2022
Q3 | $287K | Sell |
12,600
-22,800
| -64% | -$460K | ﹤0.01% | 3230 |
|
|
2022
Q2 | $638K | Sell |
35,400
-28,800
| -45% | -$513K | ﹤0.01% | 3001 |
|
|
2022
Q1 | $1.72M | Buy |
64,200
+51,700
| +414% | +$963K | ﹤0.01% | 2347 |
|
|
2021
Q4 | $367K | Buy |
+12,500
| New | +$621K | ﹤0.01% | 3247 |
|
|
2020
Q4 | – | Sell |
-20,900
| Closed | -$1.54M | – | 3530 |
|
|
2020
Q3 | $1.54M | Buy |
20,900
+11,400
| +120% | +$675K | ﹤0.01% | 2273 |
|
|
2020
Q2 | $694K | Buy |
+9,500
| New | +$577K | ﹤0.01% | 2731 |
|
Other funds holding IGMS
Renaissance Technologies's IGMS Position: Q3 2025 in Review
Renaissance Technologies sold out of IGM Biosciences (IGMS) in Q3 2025, closing a stake of 117,734 shares — an estimated $132K sold.
Renaissance Technologies first reported a position in IGMS in Q2 2020 and held it in 17 quarters. The position peaked at $1.72M in Q1 2022. 1 fund tracked by Wall St. Rank holds IGMS as of Q3 2025.
- Renaissance Technologies reported no remaining IGM Biosciences position as of Q3 2025 after selling out during the quarter.
- Renaissance Technologies sold 117,734 IGM Biosciences shares in Q3 2025, an estimated $132K.
- Renaissance Technologies first reported a position in IGM Biosciences in Q2 2020 and held it in 17 quarters.
- Renaissance Technologies's IGM Biosciences position peaked at $1.72M in Q1 2022.
- 1 fund tracked by Wall St. Rank held IGM Biosciences as of Q3 2025.
Based on Renaissance Technologies's 13F filing for Q3 2025, filed 13 Nov 2025.